Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Mar;186(3):564-574.
doi: 10.1111/bjd.20805. Epub 2021 Nov 28.

Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients

Affiliations
Free article
Multicenter Study

Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients

S Georgin-Lavialle et al. Br J Dermatol. 2022 Mar.
Free article

Abstract

Background: A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome').

Objectives: To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome.

Methods: One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded.

Results: The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis.

Conclusions: VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.

PubMed Disclaimer

Comment in

Similar articles

  • VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort.
    García-Escudero P, López-Gómez M, López BM, Dorta AG, Frade-Sosa B, Lizarzaburu MS, Rúa-Figueroa Í, Fiallo DV, Toyos Sáenz de Miera FJ, Melero-Gonzalez RB, Dios Santos D, Miranda JA, Belando CG, Boselli G, Boteanu AL, Villalobos L, Selaya CC, Sieiro Santos C, Álvarez ED, Font J, Alonso ER, Araguás ET, Merayo EE, Rodriguez-Laguna M, Monjo I, Gómez IV, Vela-Casasempere P, Merino C, Martínez MI, Beriain JÁH, Ruiz-Román A, Calvo-Alén J. García-Escudero P, et al. Rheumatology (Oxford). 2025 Jun 1;64(6):3747-3755. doi: 10.1093/rheumatology/keaf094. Rheumatology (Oxford). 2025. PMID: 39937690
  • Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
    Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, Ospina Cardona D, Rominger E, Hoffmann P, Le MT, Deng Z, Quinn KA, Rose E, Tsai WL, Wigerblad G, Goodspeed W, Jones A, Wilson L, Schnappauf O, Laird RS, Kim J, Allen C, Sirajuddin A, Chen M, Gadina M, Calvo KR, Kaplan MJ, Colbert RA, Aksentijevich I, Young NS, Savic S, Kastner DL, Ombrello AK, Beck DB, Grayson PC. Ferrada MA, et al. Arthritis Rheumatol. 2021 Oct;73(10):1886-1895. doi: 10.1002/art.41743. Epub 2021 Aug 31. Arthritis Rheumatol. 2021. PMID: 33779074
  • VEXAS Syndrome.
    Hadjadj J, Beck D. Hadjadj J, et al. 2025 May 15. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2025 May 15. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 40373178 Free Books & Documents. Review.
  • VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
    Neupane K, Jayarangaiah A, Zhang Y, Kumar A. Neupane K, et al. BMJ Case Rep. 2022 Dec 22;15(12):e251089. doi: 10.1136/bcr-2022-251089. BMJ Case Rep. 2022. PMID: 36549759 Free PMC article.
  • Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
    Guerrero-Bermúdez CA, Cardona-Cardona AF, Ariza-Parra EJ, Arostegui JI, Mensa-Vilaro A, Yague J, Vásquez G, Muñoz-Vahos CH. Guerrero-Bermúdez CA, et al. Clin Rheumatol. 2022 Nov;41(11):3565-3572. doi: 10.1007/s10067-022-06338-1. Epub 2022 Aug 20. Clin Rheumatol. 2022. PMID: 35986821 Review.

Cited by

References

    1. Beck DB, Ferrada MA, Sikora KA et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020; 383:2628-38.
    1. van der Made CI, Potjewijd J, Hoogstins A et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of VEXAS patients. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.05.014.
    1. Ferrada MA, Sikora KA, Luo Y et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS syndrome. Arthritis Rheumatol 2021; 73:1886-95.
    1. Tsuchida N, Kunishita Y, Uchiyama Y et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220090.
    1. Bourbon E, Heiblig M, Gerfaud-Valentin M et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021; 137:3682-4.

Publication types

MeSH terms

Substances